Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
et al,
"Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies",
Journal of Clinical Immunology,
2022.
| DOI: | 10.1007/s10875-022-01252-2 |
[en]
T. Meyer,
P. Stubbemann,
C. Thibeault,
O. Staudacher,
D. Niemeyer,
J. Jansen,
B. Mühlemann,
J. Doehn,
C. Tabeling,
C. Nusshag,
C. Hirzel,
D. S. Sanchez,
A. Nieters,
A. Lother,
D. Duerschmied,
N. Schallner,
J. Lieberum,
D. August,
S. Rieg,
V. Falcone,
H. Hengel,
U. Kölsch,
N. Unterwalder,
R. Hübner,
T. C. Jones,
N. Suttorp,
C. Drosten,
K. Warnatz,
T. Spinetti,
J. C. Schefold,
T. Dörner,
L. E. Sander,
V. Corman,
U. Merle,
P. Group,
F. Kurth,
H. Bernuth,
C. Meisel and
C. Goffinet,
"Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies",
J. Clin. Immunol.,
vol. 42,
no. 6,
pp. 1111—1129,
Aug.
2022.
Springer Science and Business Media LLC.
Abstract:
PURPOSE: Six to 19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions. METHODS: We analyzed sera of 430 COVID-19 patients from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome. RESULTS: The prevalence of neutralizing AABs to IFN-$\alpha$ and IFN-$ømega$ in COVID-19 patients from all cohorts was 4.2% (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs were detectable exclusively in critically affected (max. WHO score 6-8), predominantly male (83%) patients (7.6%, 18/237 for IFN-$\alpha$-AABs and 4.6%, 11/237 for IFN-$ømega$-AABs in 237 patients with critical COVID-19). IFN-AABs were present early post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with lower probability of survival (7.7% versus 80.9% in patients without IFN-AABs). TPE reduced levels of IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients compared to those not undergoing TPE. CONCLUSION: IFN-AABs may serve as early biomarker for the development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies.
| DOI: | 10.1007/s10875-022-01252-2 |
| Pubmed: | 35511314 |
Abstract:
PURPOSE: Six to 19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions. METHODS: We analyzed sera of 430 COVID-19 patients from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome. RESULTS: The prevalence of neutralizing AABs to IFN-$\alpha$ and IFN-$ømega$ in COVID-19 patients from all cohorts was 4.2% (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs were detectable exclusively in critically affected (max. WHO score 6-8), predominantly male (83%) patients (7.6%, 18/237 for IFN-$\alpha$-AABs and 4.6%, 11/237 for IFN-$ømega$-AABs in 237 patients with critical COVID-19). IFN-AABs were present early post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with lower probability of survival (7.7% versus 80.9% in patients without IFN-AABs). TPE reduced levels of IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients compared to those not undergoing TPE. CONCLUSION: IFN-AABs may serve as early biomarker for the development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies.
[en]
M. Guarino,
V. Cossiga,
I. Esposito,
A. Furno and
F. Morisco,
"Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!",
Journal of Hepatology,
vol. 76,
no. 1,
pp. 237—239,
Jan.
2022.
| DOI: | 10.1016/j.jhep.2021.07.034 |
| Datei: | https://www.sciencedirect.com/science/article/pii/S0168827821019619 |
M. Pietzner,
R. L. Chua,
E. Wheeler,
K. Jechow,
H. Radbruch and
e. a. Trump,
"ELF5 is a respiratory epithelial cell-specific risk gene for severe COVID-19",
medRxiv,
2022.
| DOI: | 10.1101/2022.01.17.22269283 |
S. Hopff,
K. Tilch,
M. Kraus,
L. Lorenz-Depiereux,
G. Anton,
K. Appel,
T. Bahmer,
A. Bartschke,
C. Bellinghausen,
I. Bernemann and
D. Stahl,
"Ethical and coordinative challenges in setting up a national cohort study exemplified by the German National Pandemic Cohort Network (NAPKON)",
Abstract ECCMID 2022,
2022.
K. Antoniou,
E. Vasarmidi,
A. Russell,
B. Crestani,
M. Delcroix,
A. Dinh-Xuan,
V. Poletti,
N. Sverzellati,
M. Vitacca,
M. Witzenrath,
T. Tonia and
A. Spanevello,
"European Respiratory Society statement on long COVID follow-up",
Eur Respir J,
vol. 60,
no. 2,
pp. 2102174,
2022.
| DOI: | 10.1183/13993003.02174-2021 |
L. Krüger,
J. Klein,
F. Tobian and
D. Stahl,
"Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2",
Infection,
vol. 50,
2022.
| DOI: | 10.1007/s15010-021-01681-y |
| Datei: | https://doi.org/10.1007/s15010-021-01681-y |
M. Hoffmann and
et al,
"Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy",
mBio,
2022.
| DOI: | 10.1128/mbio.00364-22 |
[en]
J. Menger,
S. Apostolidou,
C. Edler,
I. Kniep,
R. Kobbe,
D. Singer and
J. Sperhake,
"Fatal outcome of SARS-CoV-2 infection (B1.1.7) in a 4-year-old child",
International Journal of Legal Medicine,
vol. 136,
no. 1,
pp. 189—192,
Jan.
2022.
| DOI: | 10.1007/s00414-021-02687-9 |
| Datei: | https://doi.org/10.1007/s00414-021-02687-9 |
[en]
T. J. Hartung,
C. Neumann,
T. Bahmer,
I. Chaplinskaya-Sobol,
M. Endres,
J. Geritz,
K. G. Haeusler,
P. U. Heuschmann,
H. Hildesheim,
A. Hinz,
S. Hopff,
A. Horn,
M. Krawczak,
L. Krist,
J. Kudelka,
W. Lieb,
C. Maetzler,
A. Mehnert-Theuerkauf,
F. A. Montellano,
C. Morbach,
S. Schmidt,
S. Schreiber,
F. Steigerwald,
S. Störk,
W. Maetzler and
C. Finke,
"Fatigue and cognitive impairment after COVID-19: A prospective multicentre study",
EClinicalMedicine,
vol. 53,
no. 101651,
pp. 101651,
Nov.
2022.
Elsevier BV.
Abstract:
Background: Reliable estimates of frequency, severity and associated factors of both fatigue and cognitive impairment after COVID-19 are needed. Also, it is not clear whether the two are distinct sequelae of COVID-19 or part of the same syndrome." Methods: In this prospective multicentre study, frequency of post-COVID fatigue and cognitive impairment were assessed in n = 969 patients (535 [55%] female) $\geq$6 months after SARS-CoV-2 infection with the FACIT-Fatigue scale (cut-off $łeq$30) and Montreal Cognitive Assessment ($łeq$25 mild, $łeq$17 moderate impairment) between November 15, 2020 and September 29, 2021 at University Medical Center Schleswig-Holstein, Campus Kiel and University Hospital W"urzburg in Germany. 969 matched non-COVID controls were drawn from a pre-pandemic, randomised, Germany-wide population survey which also included the FACIT-Fatigue scale. Associated sociodemographic, comorbid, clinical, psychosocial factors and laboratory markers were identified with univariate and multivariable linear regression models. Findings: On average 9 months after infection, 19% of patients had clinically relevant fatigue, compared to 8% of matched non-COVID controls (p < 0.001). Factors associated with fatigue were female gender, younger age, history of depression and the number of acute COVID symptoms. Among acute COVID symptoms, altered consciousness, dizziness and myalgia were most strongly associated with long-term fatigue. Moreover, 26% of patients had mild and 1% had moderate cognitive impairment. Factors associated with cognitive impairment were older age, male gender, shorter education and a history of neuropsychiatric disease. There was no significant correlation between fatigue and cognitive impairment and only 5% of patients suffered from both conditions. Interpretation: Fatigue and cognitive impairment are two common, but distinct sequelae of COVID-19 with potentially separate pathophysiological pathways. Funding: German Federal Ministry of Education and Research (BMBF).
| DOI: | 10.1016/j.eclinm.2022.101651 |
| Pubmed: | 36133318 |
Abstract:
Background: Reliable estimates of frequency, severity and associated factors of both fatigue and cognitive impairment after COVID-19 are needed. Also, it is not clear whether the two are distinct sequelae of COVID-19 or part of the same syndrome." Methods: In this prospective multicentre study, frequency of post-COVID fatigue and cognitive impairment were assessed in n = 969 patients (535 [55%] female) $\geq$6 months after SARS-CoV-2 infection with the FACIT-Fatigue scale (cut-off $łeq$30) and Montreal Cognitive Assessment ($łeq$25 mild, $łeq$17 moderate impairment) between November 15, 2020 and September 29, 2021 at University Medical Center Schleswig-Holstein, Campus Kiel and University Hospital W"urzburg in Germany. 969 matched non-COVID controls were drawn from a pre-pandemic, randomised, Germany-wide population survey which also included the FACIT-Fatigue scale. Associated sociodemographic, comorbid, clinical, psychosocial factors and laboratory markers were identified with univariate and multivariable linear regression models. Findings: On average 9 months after infection, 19% of patients had clinically relevant fatigue, compared to 8% of matched non-COVID controls (p < 0.001). Factors associated with fatigue were female gender, younger age, history of depression and the number of acute COVID symptoms. Among acute COVID symptoms, altered consciousness, dizziness and myalgia were most strongly associated with long-term fatigue. Moreover, 26% of patients had mild and 1% had moderate cognitive impairment. Factors associated with cognitive impairment were older age, male gender, shorter education and a history of neuropsychiatric disease. There was no significant correlation between fatigue and cognitive impairment and only 5% of patients suffered from both conditions. Interpretation: Fatigue and cognitive impairment are two common, but distinct sequelae of COVID-19 with potentially separate pathophysiological pathways. Funding: German Federal Ministry of Education and Research (BMBF).
S. Woon,
M. Sheppard and
et al,
"First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction",
J Clin Immunol,
2022.
| DOI: | 10.1007/s10875-021-01187-0 |
S. Von Stillfried,
R. Bülow,
R. Röhrig,
P. Boor and
D. Collaborators,
"First report from the German COVID-19 autopsy registry",
The Lancet Regional Health - Europe,
pp. 100330,
2022.
| DOI: | 10.1016/j.lanepe.2022.100330 |
[eng]
S. Stillfried,
R. D. Bülow,
R. Röhrig,
P. Boor and
D. C. COVID-19 Autopsies (DeRegCOVID),
"First report from the German COVID-19 autopsy registry",
The Lancet Regional Health. Europe,
vol. 15,
pp. 100330,
Apr.
2022.
| DOI: | 10.1016/j.lanepe.2022.100330 |
F. Steinbeis,
P. Knape,
M. Mittermaier,
E. Helbig,
P. Tober-Lau,
C. Thibeault,
L. Lippert,
W. Xiang,
M. Müller-Plathe,
S. Steinbrecher and
D. Stahl,
"Functional limitations 12 months after SARS-CoV-2 infection correlate with initial disease severity: An observational study of cardiopulmonary exercise capacity testing in COVID-19 convalescents",
Respir Med,
vol. 202,
pp. 106968,
2022.
| DOI: | 10.1016/j.rmed.2022.106968 |
L. Rosenau,
R. W. Majeed,
J. Ingenerf,
A. Kiel,
B. Kroll,
T. Köhler,
H. Prokosch and
J. Gruendner,
"Generation of a Fast Healthcare Interoperability Resources (FHIR)-based Ontology for federated Feasibility Queries in the context of COVID-19: An automated approach",
JMIR Med Inform,
vol. 10,
no. 4,
pp. e35789,
Apr.
2022.
| DOI: | https://doi.org/10.2196/35789 |
A. Kühnapfel,
K. Horn,
U. Klotz,
M. Kiehntopf,
M. Rosolowski,
M. Loeffler,
N. Suttorp,
M. Witzenrath and
M. Scholz,
"Genetic Regulation of Cytokine Response in Patients with Acute Community-Acquired Pneumonia",
Genes (Basel),
vol. 13,
no. 1,
pp. 111,
2022.
| DOI: | 10.3390/genes13010111 |
A. Kühnapfel,
K. Horn,
U. Klotz,
M. Kiehntopf,
M. Rosolowski,
M. Loeffler,
N. Suttorp,
M. Witzenrath and
M. Scholz,
"Genetic Regulation of Cytokine Response in Patients with Acute Community-Acquired Pneumonia. Genes (Basel).",
2022.
[en]
K. Hirschbühl,
T. Schaller,
B. Märkl,
R. Claus,
E. Sipos,
L. Rentschler,
A. Maccagno,
B. Grosser,
E. Kling,
M. Neidig,
T. Kröncke,
O. Spring,
G. Braun,
H. Bösmüller,
M. Seidl,
I. Esposito,
J. Pablik,
J. Hilsenbeck,
P. Boor,
M. Beer,
S. Dintner and
C. Wylezich,
"High viral loads: what drives fatal cases of COVID-19 in vaccinees? – an autopsy study",
Modern Pathology,
vol. 35,
no. 8,
pp. 1013—1021,
Aug.
2022.
Abstract:
The rate of SARS-CoV-2 infections in vaccinees has become a relevant serious issue. This study aimed to determine the causes of death, histological organ alteration, and viral spread in relation to demographic, clinical-pathological, viral variants, and vaccine types for deceased individuals with proven SARS-CoV-2 infection after vaccination who died between January and November 2021. Twenty-nine consecutively collected cases were analyzed and compared to 141 nonvaccinated control cases. Autopsies were performed on 16 partially and 13 fully vaccinated individuals. Most patients were elderly and suffered from several relevant comorbidities. Real-time RT-PCR (RT-qPCR) identified a significantly increased rate of generalized viral dissemination within organ systems in vaccinated cases versus nonvaccinated cases (45% vs. 16%, respectively; P = 0.008) mainly with Ct-values of higher than 25 in non-respiratory samples. However, vaccinated cases also showed high viral loads, reaching Ct-values below 10, especially in the upper airways and lungs. This was accompanied by high rates of pulmonal bacterial or mycotic superinfections and the occurrence of immunocompromising factors, such as malignancies, immunosuppressive drug intake, or decreased immunoglobulin levels. All these findings were particularly accentuated in partially vaccinated patients compared to fully vaccinated individuals. The virus dissemination observed in our case study may indicate that patients with an impaired immune system have a decreased ability to eliminate the virus. However, the potential role of antibody-dependent enhancement must also be ruled out in future studies. Fatal cases of COVID-19 in vaccinees were rare and often associated with severe comorbidities or other immunosuppressive conditions.
| DOI: | 10.1038/s41379-022-01069-9 |
| Datei: | https://www.nature.com/articles/s41379-022-01069-9 |
Abstract:
The rate of SARS-CoV-2 infections in vaccinees has become a relevant serious issue. This study aimed to determine the causes of death, histological organ alteration, and viral spread in relation to demographic, clinical-pathological, viral variants, and vaccine types for deceased individuals with proven SARS-CoV-2 infection after vaccination who died between January and November 2021. Twenty-nine consecutively collected cases were analyzed and compared to 141 nonvaccinated control cases. Autopsies were performed on 16 partially and 13 fully vaccinated individuals. Most patients were elderly and suffered from several relevant comorbidities. Real-time RT-PCR (RT-qPCR) identified a significantly increased rate of generalized viral dissemination within organ systems in vaccinated cases versus nonvaccinated cases (45% vs. 16%, respectively; P = 0.008) mainly with Ct-values of higher than 25 in non-respiratory samples. However, vaccinated cases also showed high viral loads, reaching Ct-values below 10, especially in the upper airways and lungs. This was accompanied by high rates of pulmonal bacterial or mycotic superinfections and the occurrence of immunocompromising factors, such as malignancies, immunosuppressive drug intake, or decreased immunoglobulin levels. All these findings were particularly accentuated in partially vaccinated patients compared to fully vaccinated individuals. The virus dissemination observed in our case study may indicate that patients with an impaired immune system have a decreased ability to eliminate the virus. However, the potential role of antibody-dependent enhancement must also be ruled out in future studies. Fatal cases of COVID-19 in vaccinees were rare and often associated with severe comorbidities or other immunosuppressive conditions.
R. Dannebaum,
P. Suwalski,
H. Asgharian,
Z. G. Du,
H. Lin,
J. Weiner,
M. Holtgrewe,
C. Thibeault,
M. Müller,
X. Wang and
D. Stahl,
"Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19",
EClinicalMedicine,
vol. 48,
pp. 101438,
2022.
| DOI: | 10.1016/j.eclinm.2022.101438 |
R. Dannebaum,
P. Suwalski,
H. Asgharian,
Z. G. Du,
J. Weiner,
M. Holtgrewe,
C. Thibeault,
M. Müller,
X. Wang,
J. Saccomanno,
J. Doehn,
R. Hübner,
N. Suttorp,
M. Witzenrath,
S. Hippenstiel,
L. E. Sander,
F. Kurth,
P. Group,
H. Lin,
Z. Karadeniz,
B. Hinzmann,
A. Blüher,
S. Siemann,
D. Telman,
C. Skurk,
W. Poller,
D. Beule,
T. Guettouche,
U. Landmesser,
J. Berka,
K. Luong,
F. Rubelt and
B. Heidecker,
"Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19.",
EClinicalMedicine.2022;48:101438,
2022.
K. Hönzke,
B. Obermayer,
C. Mache,
D. Fathykova,
M. Kessler,
S. Dökel,
E. Wyler,
M. Baumgardt,
A. Löwa,
K. Hoffmann and
D. Stahl,
"Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages",
Eur Respir J,
vol. 60,
no. 6,
pp. 2102725,
2022.
| DOI: | 10.1183/13993003.02725-2021 |
K. Hönzke,
B. Obermayer,
C. Mache,
D. Fathykova,
M. Kessler and
e. a. Dökel,
"Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages",
Eur Respir J,
vol. 60,
no. 6,
pp. 2102725,
2022.
| DOI: | 10.1183/13993003.02725-2021 |
[en]
A. W. Wolff,
B. Haller,
A. F. Demleitner,
E. Westenberg and
P. Lingor,
"Impact of the COVID-19 pandemic on patients with Parkinson's
Disease from the perspective of treating physicians-A nationwide
cross-sectional study",
Brain Sci.,
vol. 12,
no. 3,
pp. 353,
Mä.
2022.
MDPI AG.
Abstract:
The COVID-19 pandemic has posed challenges to maintaining medical care for patients with Parkinson's disease (PD). The Parkinson's Disease during the COVID-19 Pandemic (ParCoPa) survey was conducted as an online, nationwide, cross-sectional survey from December 2020 to March 2021 and aimed to assess the impact of the pandemic on the medical care of PD patients from the physicians' perspective. Invitations containing a randomly generated registration code were mailed to healthcare professionals from sixty-seven specialty centers in Germany. Confounders for the worsening of subjective treatment quality, perceived health risk due to the profession, and adequate protective measures against SARS-CoV-2 were assessed using logistic regression analysis. Of all forty physicians who responded, 87.5% reported a worsening of motor and nonmotor symptoms in their patients, 97.5% experienced cancellation of appointments, and difficulties in organizing advanced and supplementary therapies were reported by over 95%. Participants offered alternative consultation options, mostly in the form of telephone (77.5%) or online (64.1%) consultations, but telephone consultations were the most accepted by patients ("broadly accepted", 40.0%). We identified pandemic-related deficits in providing care for patients with PD and areas of improvement to ensure continued care for this vulnerable patient population.
Abstract:
The COVID-19 pandemic has posed challenges to maintaining medical care for patients with Parkinson's disease (PD). The Parkinson's Disease during the COVID-19 Pandemic (ParCoPa) survey was conducted as an online, nationwide, cross-sectional survey from December 2020 to March 2021 and aimed to assess the impact of the pandemic on the medical care of PD patients from the physicians' perspective. Invitations containing a randomly generated registration code were mailed to healthcare professionals from sixty-seven specialty centers in Germany. Confounders for the worsening of subjective treatment quality, perceived health risk due to the profession, and adequate protective measures against SARS-CoV-2 were assessed using logistic regression analysis. Of all forty physicians who responded, 87.5% reported a worsening of motor and nonmotor symptoms in their patients, 97.5% experienced cancellation of appointments, and difficulties in organizing advanced and supplementary therapies were reported by over 95%. Participants offered alternative consultation options, mostly in the form of telephone (77.5%) or online (64.1%) consultations, but telephone consultations were the most accepted by patients ("broadly accepted", 40.0%). We identified pandemic-related deficits in providing care for patients with PD and areas of improvement to ensure continued care for this vulnerable patient population.
B. Sedlmayr,
M. Sedlmayr,
C. Schüttler and
et al,
"Improving collaborative COVID-19 research of University Hospitals in Germany: Formative usability evaluation of the CODEX-Feasibility Portal",
Appl Clin Inform,
vol. 13,
pp. 400—409,
2022.
| DOI: | 10.1055/s-0042-1744549 |
P. R. Wratil,
N. A. Schmacke,
A. Osterman and
et al,
"In-depth profiling of COVID-19 risk factors and preventive measures in healthcare workers",
Infection,
vol. 50,
2022.
| DOI: | 10.1007/s15010-021-01672-z |
N. Dragano,
M. Reuter,
A. Peters,
M. Engels,
B. Schmidt,
K. Greiser,
B. Bohn,
S. Riedel-Heller,
A. Karch,
R. Mikolajczyk,
G. Krause,
O. Lang,
L. Panreck,
M. Rietschel,
H. Brenner,
B. Fischer,
C. Franzke,
S. Gastell,
B. Holleczek,
K. Jöckel,
R. Kaaks,
T. Keil,
A. Kluttig,
O. Kuß,
N. Legath,
M. Leitzmann,
W. Lieb,
C. Meinke-Franze,
K. Michels,
N. Obi,
T. Pischon,
I. Feinkohl,
S. Rospleszcz,
T. Schikowski,
M. Schulze,
A. Stang,
H. Völzke,
S. Willlich,
K. Wirkner,
H. Zeeb and
K. Berger,
"Increase in mental disorders during the COVID-19 pandemic - the role of occupational and financial strains. An analysis of the German National Cohort (NAKO) Study",
Deutsches Ärzteblatt International,
vol. 119,
pp. 179–187,
2022.
| DOI: | 10.3238/arztebl.m2022.0133 |
A. Bludau,
S. Heinemann,
A. Mardiko,
H. Kaba,
A. Leha,
N. von Maltzahn,
N. Mutters,
R. Leistner,
F. Mattner and
S. Scheithauer,
"Infection control strategies for patients and accompanying persons during the COVID-19 pandemic in German hospitals: a cross-sectional study in March-April 2021",
The Journal of hospital infection,
vol. 125,
pp. 28—36,
2022.
| DOI: | 10.1016/j.jhin.2022.03.014 |
A. Bludau,
S. Heinemann,
A. Mardiko,
H. Kaba,
A. Leha,
N. von Maltzahn,
N. Mutters,
R. Leistner,
F. Mattner and
S. Scheithauer,
"Infection control strategies for patients and accompanying persons during the COVID-19 pandemic in German hospitals: a cross-sectional study in March–April 2021",
Journal of Hospital Infection,
vol. 125,
pp. 28-36,
2022.
| DOI: | 10.1016/j.jhin.2022.03.014. |
A. Bludau,
S. Heinemann,
A. A. Mardiko,
H. E. J. Kaba,
A. Leha,
N. Maltzahn,
N. T. Mutters,
R. Leistner,
F. Mattner and
S. Scheithauer,
"Infection control strategies for patients and accompanying persons during the COVID-19 pandemic in German hospitals: a cross-sectional study in March–April 2021",
Journal of Hospital Infection,
2022.
| DOI: | 10.1016/j.jhin.2022.03.014 |
| Datei: | https://doi.org/10.1016/j.jhin.2022.03.014 |
A. Bludau,
S. Heinemann,
A. Mardiko,
H. Kaba,
A. Leha,
N. von Maltzahn,
N. Mutters,
R. Leistner,
F. Mattner and
S. Scheithauer,
"Infection control strategies for patients and accompanying persons during the COVID-19 pandemic in German hospitals: a cross-sectional study in March–April 2021",
Journal of Hospital Infection,
vol. 125,
pp. 28-36,
2022.
| DOI: | 10.1016/j.jhin.2022.03.014. |
T. Houwaart,
S. Belhaj,
E. Tawalbeh,
D. Nagels,
Y. Fröhlich,
P. Finzer,
P. Ciruela,
A. Sabrià,
M. Herrero,
C. Andrés,
A. Antón,
A. Benmoumene,
D. Asskali,
H. Haidar,
J. von Dahlen,
J. Nicolai,
M. Stiller,
J. Blum,
C. Lange,
C. Adelmann,
B. Schroer,
U. Osmers,
C. Grice,
P. Kirfel,
H. Jomaa,
D. Strelow,
L. Hülse,
M. Pigulla,
P. Kreuzer,
A. Tyshaieva,
J. Weber,
T. Wienemann,
M. Kohns Vasconcelos,
K. Hoffmann,
N. Lübke,
S. Hauka,
M. Andree,
C. Scholz,
N. Jazmati,
K. Göbels,
R. Zotz,
K. Pfeffer,
J. Timm,
L. Ehlkes,
A. Walker,
A. Dilthey and
German COVID-19 OMICS Initiative (DeCOI),
"Integrated genomic surveillance enables tracing of person-to-person SARS-CoV-2 transmission chains during community transmission and reveals extensive onward transmission of travel-imported infections, Germany, June to July 2021",
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,
vol. 27,
no. 43,
2022.
| DOI: | 10.2807/1560-7917.ES.2022.27.43.2101089 |
T. Houwaart,
S. Belhaj,
E. Tawalbeh,
D. Nagels,
Y. Fröhlich,
P. Finzer,
P. Ciruela,
A. Sabrià,
M. Herrero,
C. Andrés,
A. Antón,
A. Benmoumene,
D. Asskali,
H. Haidar,
J. von Dahlen,
J. Nicolai,
M. Stiller,
J. Blum,
C. Lange,
C. Adelmann,
B. Schroer,
U. Osmers,
C. Grice,
P. Kirfel,
H. Jomaa,
D. Strelow,
L. Hülse,
M. Pigulla,
P. Kreuzer,
A. Tyshaieva,
J. Weber,
T. Wienemann,
M. Kohns Vasconcelos,
K. Hoffmann,
N. Lübke,
S. Hauka,
M. Andree,
C. Scholz,
N. Jazmati,
K. Göbels,
R. Zotz,
K. Pfeffer,
J. Timm,
L. Ehlkes,
A. Walker,
A. Dilthey and
German COVID-19 OMICS Initiative (DeCOI),
"Integrated genomic surveillance enables tracing of person-to-person SARS-CoV-2 transmission chains during community transmission and reveals extensive onward transmission of travel-imported infections, Germany, June to July 2021",
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,
vol. 27,
no. 43,
2022.
| DOI: | 10.2807/1560-7917.ES.2022.27.43.2101089 |
H. Torsten,
B. Samir,
T. Emran,
N. Dirk,
F. Yara,
F. Patrick,
C. Pilar,
S. Aurora,
H. Mercè,
A. Cristina,
A. Andrés,
B. Assia,
A. Dounia,
H. Hussein,
Janina,
N. Jessica,
S. Mygg,
B. Jacqueline,
L. Christian,
A. Carla,
S. Britta,
O. Ute,
G. Christiane,
K. P. P.,
J. Hassan,
S. Daniel,
H. Lisanna,
P. Moritz,
K. Pascal,
T. Alona,
W. Jonas,
W. Tobias,
K. V. Malte,
H. Katrin,
L. Nadine,
H. Sandra,
A. Marcel,
S. C. Juergen,
J. Nathalie,
G. Klaus,
Z. Rainer,
P. Klaus,
T. Joerg,
E. Lutz,
W. Andreas,
D. A. T. and
G. C. O. I. (DeCOI),
"Integrated genomic surveillance enables tracing of person-to-person SARS-CoV-2 transmission chains during community transmission and reveals extensive onward transmission of travel-imported infections, Germany, June to July 2021.",
Eurosurveillance,
2022.
| DOI: | 10.2807/1560-7917.ES.2022.27.43.2101089 |
| Datei: | https://doi.org/10.2807/1560-7917.ES.2022.27.43.2101089 |
A. Müller,
H. Haneke,
V. Kirchberger,
G. Mastella,
M. Dommasch,
U. Merle,
O. Heinze,
A. Siegmann,
C. Spinner,
A. Buiatti,
K. Laugwitz,
G. Schmidt and
E. Martens,
"Integration of mobile sensors in a telemedicine hospital system: Remote-monitoring in COVID-19 patients",
Journal of Public Health,
vol. 30,
no. 1,
pp. 93—97,
2022.
| DOI: | 10.1007/s10389-021-01655-2 |
M. Kantauskaite and
et al,
"Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients",
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
vol. 22,
pp. 634–639,
2022.
| DOI: | 10.1111/ajt.16851 |
Oorschot and
D. Stahl,
"Interaktive Homepage für Trauernde in Pandemiezeiten",
Schmerz, Nervenarzt, Forum DKG, Urologe, Onkologe,
2022.
P. Dönges,
J. Wagner,
S. Contreras,
E. N. Iftekhar,
S. Bauer,
S. B. Mohr,
J. Dehning,
A. C. Valdez,
M. Kretzschmar,
M. Mäs,
K. Nagel and
V. Priesemann,
"Interplay Between Risk Perception, Behavior, and COVID-19 Spread",
Frontiers in Physics,
vol. 10,
pp. 842180,
2022.
| DOI: | 10.3389/fphy.2022.842180 |
[eng]
S. Stillfried,
R. D. Bülow,
R. Röhrig,
P. Meybohm,
P. Boor and
D. C. COVID-19 Autopsies (DeRegCOVID),
"Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure: a nationwide register study report",
Critical Care (London, England),
vol. 26,
no. 1,
pp. 83,
Mä.
2022.
Abstract:
BACKGROUND: In severe cases, SARS-CoV-2 infection leads to acute respiratory distress syndrome (ARDS), often treated by extracorporeal membrane oxygenation (ECMO). During ECMO therapy, anticoagulation is crucial to prevent device-associated thrombosis and device failure, however, it is associated with bleeding complications. In COVID-19, additional pathologies, such as endotheliitis, may further increase the risk of bleeding complications. To assess the frequency of bleeding events, we analyzed data from the German COVID-19 autopsy registry (DeRegCOVID). METHODS: The electronic registry uses a web-based electronic case report form. In November 2021, the registry included N = 1129 confirmed COVID-19 autopsy cases, with data on 63 ECMO autopsy cases and 1066 non-ECMO autopsy cases, contributed from 29 German sites. FINDINGS: The registry data showed that ECMO was used in younger male patients and bleeding events occurred much more frequently in ECMO cases compared to non-ECMO cases (56% and 9%, respectively). Similarly, intracranial bleeding (ICB) was documented in 21% of ECMO cases and 3% of non-ECMO cases and was classified as the immediate or underlying cause of death in 78% of ECMO cases and 37% of non-ECMO cases. In ECMO cases, the three most common immediate causes of death were multi-organ failure, ARDS and ICB, and in non-ECMO cases ARDS, multi-organ failure and pulmonary bacterial ± fungal superinfection, ordered by descending frequency. INTERPRETATION: Our study suggests the potential value of autopsies and a joint interdisciplinary multicenter (national) approach in addressing fatal complications in COVID-19.
| DOI: | 10.1186/s13054-022-03945-x |
Abstract:
BACKGROUND: In severe cases, SARS-CoV-2 infection leads to acute respiratory distress syndrome (ARDS), often treated by extracorporeal membrane oxygenation (ECMO). During ECMO therapy, anticoagulation is crucial to prevent device-associated thrombosis and device failure, however, it is associated with bleeding complications. In COVID-19, additional pathologies, such as endotheliitis, may further increase the risk of bleeding complications. To assess the frequency of bleeding events, we analyzed data from the German COVID-19 autopsy registry (DeRegCOVID). METHODS: The electronic registry uses a web-based electronic case report form. In November 2021, the registry included N = 1129 confirmed COVID-19 autopsy cases, with data on 63 ECMO autopsy cases and 1066 non-ECMO autopsy cases, contributed from 29 German sites. FINDINGS: The registry data showed that ECMO was used in younger male patients and bleeding events occurred much more frequently in ECMO cases compared to non-ECMO cases (56% and 9%, respectively). Similarly, intracranial bleeding (ICB) was documented in 21% of ECMO cases and 3% of non-ECMO cases and was classified as the immediate or underlying cause of death in 78% of ECMO cases and 37% of non-ECMO cases. In ECMO cases, the three most common immediate causes of death were multi-organ failure, ARDS and ICB, and in non-ECMO cases ARDS, multi-organ failure and pulmonary bacterial ± fungal superinfection, ordered by descending frequency. INTERPRETATION: Our study suggests the potential value of autopsies and a joint interdisciplinary multicenter (national) approach in addressing fatal complications in COVID-19.
S. Stillfried,
R. Bülow,
R. Röhrig,
P. Meybohm and
P. Boor,
"Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure: a nationwide register study report",
Critical care (London, England),
vol. 26,
pp. 83,
2022.
| DOI: | 10.1186/s13054-022-03945-x |
B. Pauli,
J. Strupp,
K. Schloesser and
D. Stahl,
"It’s like standing in front of a prison fence – Dying during the SARS-CoV2 pandemic: A qualitative study of bereaved relatives’ experiences",
Palliative Medicine,
2022.
| DOI: | 10.1177/02692163221076355 |
[en]
E. Wyler,
K. Eschke,
G. Teixeira Alves,
S. Peidli,
F. Pott,
J. Kazmierski,
L. Michalick,
O. Kershaw,
J. Bushe,
P. Pennitz,
D. Postmus,
C. Goffinet,
J. Kreye,
S. M. Reincke,
H. Prüss,
N. Blüthgen,
A. D. Gruber,
W. M. Kuebler,
M. Witzenrath,
M. Landthaler,
G. Nouailles and
J. Trimpert,
"Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics",
Mol. Ther.,
vol. 30,
no. 5,
pp. 1952—1965,
Mai
2022.
Elsevier BV.
Abstract:
For coronavirus disease 2019 (COVID-19), effective and well-understood treatment options are still scarce. Since vaccine efficacy is challenged by novel variants, short-lasting immunity, and vaccine hesitancy, understanding and optimizing therapeutic options remains essential. We aimed at better understanding the effects of two standard-of-care drugs, dexamethasone and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, on infection and host responses. By using two COVID-19 hamster models, pulmonary immune responses were analyzed to characterize effects of single or combinatorial treatments. Pulmonary viral burden was reduced by anti-SARS-CoV-2 antibody treatment and unaltered or increased by dexamethasone alone. Dexamethasone exhibited strong anti-inflammatory effects and prevented fulminant disease in a severe disease model. Combination therapy showed additive benefits with both anti-viral and anti-inflammatory potency. Bulk and single-cell transcriptomic analyses confirmed dampened inflammatory cell recruitment into lungs upon dexamethasone treatment and identified a specifically responsive subpopulation of neutrophils, thereby indicating a potential mechanism of action. Our analyses confirm the anti-inflammatory properties of dexamethasone and suggest possible mechanisms, validate anti-viral effects of anti-SARS-CoV-2 antibody treatment, and reveal synergistic effects of a combination therapy, thus informing more effective COVID-19 therapies.
| DOI: | 10.1016/j.ymthe.2022.03.014 |
| Pubmed: | 35339689 |
Abstract:
For coronavirus disease 2019 (COVID-19), effective and well-understood treatment options are still scarce. Since vaccine efficacy is challenged by novel variants, short-lasting immunity, and vaccine hesitancy, understanding and optimizing therapeutic options remains essential. We aimed at better understanding the effects of two standard-of-care drugs, dexamethasone and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, on infection and host responses. By using two COVID-19 hamster models, pulmonary immune responses were analyzed to characterize effects of single or combinatorial treatments. Pulmonary viral burden was reduced by anti-SARS-CoV-2 antibody treatment and unaltered or increased by dexamethasone alone. Dexamethasone exhibited strong anti-inflammatory effects and prevented fulminant disease in a severe disease model. Combination therapy showed additive benefits with both anti-viral and anti-inflammatory potency. Bulk and single-cell transcriptomic analyses confirmed dampened inflammatory cell recruitment into lungs upon dexamethasone treatment and identified a specifically responsive subpopulation of neutrophils, thereby indicating a potential mechanism of action. Our analyses confirm the anti-inflammatory properties of dexamethasone and suggest possible mechanisms, validate anti-viral effects of anti-SARS-CoV-2 antibody treatment, and reveal synergistic effects of a combination therapy, thus informing more effective COVID-19 therapies.
F. P,
K. J,
P. T,
L. S,
M. V,
S. Fischer,
S. H,
D. C,
S. M,
Z. S,
S. M,
M. D,
F. GR and
A. N,
"Meaningful use of imaging resources to rule out cerebral venous sinus thrombosis after ChAdOx1 COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohort and a systematic data review.",
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
Aug.
2022.
Abstract:
Vaccin-induzierte immunthrombotische Thrombozytopenie (VITT) mit cerebraler venöser Thrombose (CVST) ist eine unwahrscheinliche (0.0005%), aber möglicherweise tödliche Komplikation nach ChAdOx1 Impfung. Andererseits gehört Kopfschmerzen zu den häufigsten Nebenwirkungen von ChAdOx1 (29,3%). Im September 2021 schlug die American Heart Association (AHA) einen diagnostischen Workflow vor, um die risikoadaptierte Verwendung von bildgebenden Ressourcen für Patienten mit neurologischen Symptomen nach ChAdOx1 zu erleichtern. Wir wollten den AHA-Workflow in einem retrospektiven Patientenkohort bewerten, der nach ChAdOx1 an vier primären Pflegekrankenhäusern in Deutschland präsentiert. Wissenschaftliche Literatur wurde für Fallberichte von VITT mit CVST nach ChAdOx1, veröffentlicht bis 1. September 2021. Einhundertdreizehn aufeinanderfolgende Patienten (77 weiblich, mittleres Alter 38,7 +/- 11,9 Jahre) wurden an unseren Instituten bewertet, darunter ein Fall von VITT mit CVST. Weitere 228 Fallberichte von VITT mit CVST werden in jüngster Literatur veröffentlicht, die Thrombozyten-Thema (225/227 berichtet) und erhöhte d-Dimer-Spiegel (100/101 berichtet) teilen. Der AHA-Workflow hätte alle VITT-Fälle mit CVST (100% Empfindlichkeit) erkannt, die für die Diagnose (NND) benötigte Anzahl betrug 1:113. Die anfängliche Auswertung von Thrombocytopenie oder erhöhten d-Dimer-Spiegeln hätte den NND auf 1:68 reduziert, ohne dass die Empfindlichkeit gekostet wäre. Daher schlagen wir vor, dass bei normalen Thrombozyten- und d-Dimerenspiegeln der Zugang zu weiteren Diagnostiken durch die etablierten klinischen Überlegungen unabhängig von der Impfungsgeschichte begrenzt werden sollte.
| DOI: | 10.1016/j.jocn.2022.05.031 |
Abstract:
Vaccin-induzierte immunthrombotische Thrombozytopenie (VITT) mit cerebraler venöser Thrombose (CVST) ist eine unwahrscheinliche (0.0005%), aber möglicherweise tödliche Komplikation nach ChAdOx1 Impfung. Andererseits gehört Kopfschmerzen zu den häufigsten Nebenwirkungen von ChAdOx1 (29,3%). Im September 2021 schlug die American Heart Association (AHA) einen diagnostischen Workflow vor, um die risikoadaptierte Verwendung von bildgebenden Ressourcen für Patienten mit neurologischen Symptomen nach ChAdOx1 zu erleichtern. Wir wollten den AHA-Workflow in einem retrospektiven Patientenkohort bewerten, der nach ChAdOx1 an vier primären Pflegekrankenhäusern in Deutschland präsentiert. Wissenschaftliche Literatur wurde für Fallberichte von VITT mit CVST nach ChAdOx1, veröffentlicht bis 1. September 2021. Einhundertdreizehn aufeinanderfolgende Patienten (77 weiblich, mittleres Alter 38,7 +/- 11,9 Jahre) wurden an unseren Instituten bewertet, darunter ein Fall von VITT mit CVST. Weitere 228 Fallberichte von VITT mit CVST werden in jüngster Literatur veröffentlicht, die Thrombozyten-Thema (225/227 berichtet) und erhöhte d-Dimer-Spiegel (100/101 berichtet) teilen. Der AHA-Workflow hätte alle VITT-Fälle mit CVST (100% Empfindlichkeit) erkannt, die für die Diagnose (NND) benötigte Anzahl betrug 1:113. Die anfängliche Auswertung von Thrombocytopenie oder erhöhten d-Dimer-Spiegeln hätte den NND auf 1:68 reduziert, ohne dass die Empfindlichkeit gekostet wäre. Daher schlagen wir vor, dass bei normalen Thrombozyten- und d-Dimerenspiegeln der Zugang zu weiteren Diagnostiken durch die etablierten klinischen Überlegungen unabhängig von der Impfungsgeschichte begrenzt werden sollte.
S. Krishnaratne,
H. Littlecott,
K. Sell,
J. Burns,
J. E. Rabe,
J. M. Stratil,
T. Litwin,
C. Kreutz,
M. Coenen,
K. Geffert,
A. H. Boger,
A. Movsisyan,
S. Kratzer,
C. Klinger,
K. Wabnitz,
B. Strahwald,
B. Verboom,
E. Rehfuess,
R. L. Biallas,
C. Jung-Sievers,
S. Voss and
L. M. Pfadenhauer,
"Measures implemented in the school setting to contain the COVID-19 pandemic: a rapid review",
Cochrane Database of Systematic Reviews,
vol. 2022,
pp. CD015029,
2022.
| DOI: | 10.1002/14651858.CD015029 |
[eng]
M. Ackermann and
D. D. Jonigk,
"Microvascular placental alterations in maternal COVID-19",
American Journal of Obstetrics and Gynecology,
vol. 226,
no. 1,
pp. 135—136,
Jan.
2022.
| DOI: | 10.1016/j.ajog.2021.06.098 |
J. Schwartz,
M. C. Reuters,
M. Schallenburger,
S. Meier,
C. Roch,
L. Werner,
B. Oorschot and
M. Neukirchen,
"Modelle guter Praxis: Alleine sterben ist ethisch nicht vertretbar",
Praxis Palliative Care,
vol. 54,
pp. 29-36,
2022.
N. Wanner,
G. Andrieux,
P. Badia-i-Mompel and
et al,
"Molecular consequences of SARS-CoV-2 liver tropism",
Nat Metab,
vol. 4,
pp. 310-319,
2022.
| DOI: | 10.1038/s42255-022-00552-6 |
[eng]
N. Wanner,
G. Andrieux,
P. Badia-I-Mompel,
C. Edler,
S. Pfefferle,
M. T. Lindenmeyer,
C. Schmidt-Lauber,
J. Czogalla,
M. N. Wong,
Y. Okabayashi,
F. Braun,
M. Lütgehetmann,
E. Meister,
S. Lu,
M. L. M. Noriega,
T. Günther,
A. Grundhoff,
N. Fischer,
H. Bräuninger,
D. Lindner,
D. Westermann,
F. Haas,
K. Roedl,
S. Kluge,
M. M. Addo,
S. Huber,
A. W. Lohse,
J. Reiser,
B. Ondruschka,
J. P. Sperhake,
J. Saez-Rodriguez,
M. Boerries,
S. S. Hayek,
M. Aepfelbacher,
P. Scaturro,
V. G. Puelles and
T. B. Huber,
"Molecular consequences of SARS-CoV-2 liver tropism",
Nature Metabolism,
vol. 4,
no. 3,
pp. 310—319,
Mä.
2022.
| DOI: | 10.1038/s42255-022-00552-6 |
H. Gruell and
et al,
"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant",
Nature Medicine,
2022.
| DOI: | 10.1038/s41591-021-01676-0 |
Z. Liu and
et al,
"Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19",
Frontiers in immunology,
vol. 13,
pp. 838132,
2022.
| DOI: | 10.3389/fimmu.2022.838132 |
T. Illig,
"NAPKON- Eine Erfolgsgeschichte",
Plenarvortrag, Nationales Biobanken Symposium,
2022.